The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Role of persistent MRD in MM and elderly AML using next-generation flow
Bruno Paiva, PhD, of the University of Navarra, Pamplona, Spain, gives us the updates from his group’s work on measurable residual disease (MRD) in multiple myeloma and elderly acute myeloid leukemia. This work looked at the clinical significance of persistent MRD, as measured by next-generation flow cytometry, of these patients with both standard- and high-risk disease. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
